Divine Hira Jewellers IPO Allotment: As the Divine Hira Jewellers IPO has been closed with an overall subscription of 3.93 times, its allotment is set to be finalised on Thursday, in the evening. Once ...

Divine Hira Jewellers IPO allotment status: The basis of allotment of shares for Divine Hira Jewellers is expected to be finalised today, Thursday, March 20, 2025. The initial public offering (IPO) of ...

CRISPR gene-editing technology offers curative potential for genetic diseases. The gene-editing market is projected to reach $30.8 billion by 2032. Top gene-editing pioneers include Intellia ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The original Gene line-up have reunited and announced their first live show in over 20 years. Read NME‘s interview with frontman Martin Rossiter below, where he discusses what to expect from the ...

The company’s innovative approach to gene therapy has garnered attention from both investors and industry partners, yet concerns about its cash position loom large over its future prospects. According ...

Regenxbio is advancing three late-stage gene therapy programs: RGX-121, RGX-202, and RGX-314. The company has completed the BLA submission for RGX-121, with potential approval by the end of 2025.

The initial public offerings of Divine Hira Jewellers, and Paradeep Parivahan remained undersubscribed on their first day of bidding, i.e. March 17. Both public issues will remain open till March 19.

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Gene Hackman had only been spotted on a few rare appearances throughout the remainder of his life. The Royal Tenenbaums star hung up his hat on his iconic film career at the age of 74, and he died ...

Forbes contributors publish independent expert analyses and insights. Dana Feldman is a Los Angeles-based reporter who covers entertainment.

By Gina Kolata Researchers have corrected a disease-causing gene mutation with a single infusion carrying a treatment that precisely targeted the errant gene. This was the first time a mutated ...